Overview
Apolipoprotein A-I (apo A-I) deficiency is a rare inherited disorder of lipoprotein metabolism caused by mutations in the APOA1 gene, which encodes the major protein component of high-density lipoprotein (HDL) cholesterol. This condition is also known as familial hypoalphalipoproteinemia or analphalipoproteinemia when HDL is completely absent. Apo A-I plays a critical role in reverse cholesterol transport — the process by which excess cholesterol is removed from tissues and transported to the liver for excretion. When apo A-I is deficient or absent, HDL cholesterol levels are markedly reduced or undetectable, leading to impaired cholesterol clearance from the body. The disease primarily affects the cardiovascular system, the eyes, and the skin. Patients are at significantly increased risk for premature coronary artery disease and atherosclerosis, often presenting with symptomatic cardiovascular events in early adulthood. Corneal opacification (corneal clouding) is a hallmark feature and may develop in childhood or early adulthood, potentially impairing vision. Some patients also develop xanthomas — yellowish deposits of cholesterol in the skin and tendons — due to abnormal lipid accumulation. In certain variants, amyloidosis affecting the kidneys, liver, or other organs has been reported, caused by deposition of amyloid fibrils derived from mutant apo A-I protein. There is currently no specific curative therapy for apo A-I deficiency. Management focuses on aggressive cardiovascular risk reduction, including lifestyle modifications (diet, exercise, smoking cessation) and lipid-lowering medications such as statins. Corneal transplantation may be considered for significant visual impairment due to corneal opacities. Regular cardiovascular monitoring and screening for complications such as amyloidosis are recommended. Research into HDL-targeted therapies and apo A-I replacement strategies is ongoing but remains largely investigational.
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Apolipoprotein A-I deficiency.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Apolipoprotein A-I deficiency at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Apolipoprotein A-I deficiency.
Community
No community posts yet. Be the first to share your experience with Apolipoprotein A-I deficiency.
Start the conversation →Latest news about Apolipoprotein A-I deficiency
Disease timeline:
New recruiting trial: LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study
A new clinical trial is recruiting patients for Apolipoprotein A-I deficiency
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Apolipoprotein A-I deficiency
What is Apolipoprotein A-I deficiency?
Apolipoprotein A-I (apo A-I) deficiency is a rare inherited disorder of lipoprotein metabolism caused by mutations in the APOA1 gene, which encodes the major protein component of high-density lipoprotein (HDL) cholesterol. This condition is also known as familial hypoalphalipoproteinemia or analphalipoproteinemia when HDL is completely absent. Apo A-I plays a critical role in reverse cholesterol transport — the process by which excess cholesterol is removed from tissues and transported to the liver for excretion. When apo A-I is deficient or absent, HDL cholesterol levels are markedly reduced
Which specialists treat Apolipoprotein A-I deficiency?
6 specialists and care centers treating Apolipoprotein A-I deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.